Aravive, Inc., based in Houston, TX, is a biopharmaceutical company that is focused on developing transformative targeted cancer therapeutics. The company is currently conducting clinical trials of batiraxcept (formerly AVB-500) in combination with standard anticancer treatments in multiple indications, including a Phase 1b/2 trial in pancreatic adenocarcinoma.
Aravive has made the decision to voluntarily delist its common stock from the Nasdaq Global Select Market and deregister its common stock under the Securities Exchange Act of 1934. This move comes after the company's stockholders approved the transfer of assets for the benefit of creditors and the dissolution and liquidation of the company, subject to the board's determination that such actions were in the best interests of the company.
Generated from the website